Disease course of neurofibromatosis type 2: a 30-year follow-up study of 353 patients seen at a single institution.
Manchester criteria
ependymoma
meningioma
neurofibromatosis type 2
vestibular schwannoma
Journal
Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420
Informations de publication
Date de publication:
01 07 2021
01 07 2021
Historique:
pubmed:
19
12
2020
medline:
5
8
2021
entrez:
18
12
2020
Statut:
ppublish
Résumé
Limited data exist on the disease course of neurofibromatosis type 2 (NF2) to guide clinical trial design. A prospective database of patients meeting NF2 diagnostic criteria, reviewed between 1990 and 2020, was evaluated. Follow-up to first vestibular schwannoma (VS) intervention and death was assessed by univariate analysis and stratified by age at onset, era referred, and inheritance type. Interventions for NF2-related tumors were assessed. Cox regression was performed to determine the relationship between individual factors from time of diagnosis to NF2-related death. Three hundred and fifty-three patients were evaluated. During 4643.1 follow-up years from diagnosis to censoring, 60 patients (17.0%) died. The annual mean number of patients undergoing VS surgery or radiotherapy declined, from 4.66 and 1.65, respectively, per 100 NF2 patients in 1990-1999 to 2.11 and 1.01 in 2010-2020, as the number receiving bevacizumab increased (2.51 per 100 NF2 patients in 2010-2020). Five patients stopped bevacizumab to remove growing meningioma or spinal schwannoma. 153/353 (43.3%) had at least one neurosurgical intervention/radiation treatment within 5 years of diagnosis. Patients asymptomatic at diagnosis had longer time to intervention and better survival compared to those presenting with symptoms. Those symptomatically presenting <16 and >40 years had poorer overall survival than those presenting at 26-39 years (P = .03 and P = .02, respectively) but those presenting between 16 and 39 had shorter time to VS intervention. Individuals with de novo constitutional variants had worse survival than those with de novo mosaic or inherited disease (P = .004). Understanding disease course improves prognostication, allowing for better-informed decisions about care.
Sections du résumé
BACKGROUND
Limited data exist on the disease course of neurofibromatosis type 2 (NF2) to guide clinical trial design.
METHODS
A prospective database of patients meeting NF2 diagnostic criteria, reviewed between 1990 and 2020, was evaluated. Follow-up to first vestibular schwannoma (VS) intervention and death was assessed by univariate analysis and stratified by age at onset, era referred, and inheritance type. Interventions for NF2-related tumors were assessed. Cox regression was performed to determine the relationship between individual factors from time of diagnosis to NF2-related death.
RESULTS
Three hundred and fifty-three patients were evaluated. During 4643.1 follow-up years from diagnosis to censoring, 60 patients (17.0%) died. The annual mean number of patients undergoing VS surgery or radiotherapy declined, from 4.66 and 1.65, respectively, per 100 NF2 patients in 1990-1999 to 2.11 and 1.01 in 2010-2020, as the number receiving bevacizumab increased (2.51 per 100 NF2 patients in 2010-2020). Five patients stopped bevacizumab to remove growing meningioma or spinal schwannoma. 153/353 (43.3%) had at least one neurosurgical intervention/radiation treatment within 5 years of diagnosis. Patients asymptomatic at diagnosis had longer time to intervention and better survival compared to those presenting with symptoms. Those symptomatically presenting <16 and >40 years had poorer overall survival than those presenting at 26-39 years (P = .03 and P = .02, respectively) but those presenting between 16 and 39 had shorter time to VS intervention. Individuals with de novo constitutional variants had worse survival than those with de novo mosaic or inherited disease (P = .004).
CONCLUSION
Understanding disease course improves prognostication, allowing for better-informed decisions about care.
Identifiants
pubmed: 33336705
pii: 6041427
doi: 10.1093/neuonc/noaa284
pmc: PMC8248850
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1113-1124Subventions
Organisme : Medical Research Council
ID : G0600485
Pays : United Kingdom
Organisme : Department of Health
ID : NIHR/CS/010/021
Pays : United Kingdom
Organisme : Department of Health
ID : IS-BRC-1215-20007
Pays : United Kingdom
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
World Neurosurg. 2015 Oct;84(4):1062-9
pubmed: 26087434
Br J Neurosurg. 2009 Jun;23(3):226-31
pubmed: 19533454
Br J Neurosurg. 2005 Feb;19(1):5-12
pubmed: 16147576
Pediatr Blood Cancer. 2020 May;67(5):e28228
pubmed: 32124552
Genet Med. 2019 Jul;21(7):1525-1533
pubmed: 30523344
Am J Hum Genet. 2002 Oct;71(4):715-23
pubmed: 12235555
J Med Genet. 2005 Jul;42(7):540-6
pubmed: 15994874
N Engl J Med. 2009 Jul 23;361(4):358-67
pubmed: 19587327
Laryngoscope. 2019 Apr;129(4):974-980
pubmed: 30456886
Otol Neurotol. 2004 Sep;25(5):811-7
pubmed: 15354016
Genet Med. 2020 Jan;22(1):53-59
pubmed: 31273341
PLoS One. 2013;8(3):e59941
pubmed: 23555840
J Neurosurg. 2012 Jul;117(1):109-17
pubmed: 22503123
Otol Neurotol. 2012 Aug;33(6):1046-52
pubmed: 22805104
Neuro Oncol. 2012 Aug;14(8):1090-6
pubmed: 22711605
J Clin Oncol. 2019 Dec 10;37(35):3446-3454
pubmed: 31626572
Neurol Neurochir Pol. 2015;49(6):367-72
pubmed: 26652870
Otol Neurotol. 2014 Jan;35(1):e50-6
pubmed: 24335938
Otol Neurotol. 2018 Mar;39(3):357-364
pubmed: 29342057
Hum Genet. 1996 Aug;98(2):203-6
pubmed: 8698343
Am J Med Genet. 1998 May 18;77(3):228-33
pubmed: 9605590
Neuropediatrics. 2005 Feb;36(1):21-34
pubmed: 15776319
Neurogenetics. 2013 May;14(2):89-98
pubmed: 23377185
J Med Genet. 1992 Dec;29(12):841-6
pubmed: 1479598
J Med Genet. 2017 Oct;54(10):657-664
pubmed: 28848060
Clin Genet. 2019 Aug;96(2):151-162
pubmed: 30993672
Q J Med. 1992 Aug;84(304):603-18
pubmed: 1484939
Arch Dis Child. 1999 Dec;81(6):496-9
pubmed: 10569966
Neurochirurgie. 2018 Nov;64(5):342-347
pubmed: 26183546
Neurooncol Pract. 2016 Dec;3(4):281-289
pubmed: 29692918
J Med Genet. 2015 Oct;52(10):699-705
pubmed: 26275417
Am J Med Genet A. 2013 Apr;161A(4):667-70
pubmed: 23322716